Evidence map›Paper›PMID 40678071›Full record

ArticleFrontiers in oncology2025

Severe hypotension induced by Almonertinib: a case report with literature review and clinical insights.

Haiyu Niu, Feixue Song, Xiaochun Zhou, Qiaoying Jin, Yating Liu, Benxin Luo, Hanwen Wei

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haiyu Niu *Department of Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Feixue Song *Department of Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Xiaochun ZhouDepartment of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Qiaoying JinCuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Yating LiuDepartment of Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Benxin LuoDepartment of Internal Medicine, The People's Hospital of Zhouqu, Gannan, China.
Hanwen WeiDepartment of Cardiology, The First People's Hospital of Lanzhou, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma is a common malignancy in clinical practice, but the coexistence of lung and gastric adenocarcinomas in a single patient is rare. This report presents the case of a 70-year-old male with a history of smoking for over 30 years, diagnosed with both lung adenocarcinoma and gastric adenocarcinoma through lung biopsy and gastroscopy. Following comprehensive evaluations and exclusion of treatment contraindications, the patient underwent a therapeutic regimen comprising Sintilimab combined with nab-paclitaxel and cisplatin. Genetic testing of the lung cancer tissue identified mutations in the epidermal growth factor receptor (

Indexed as

AlmonertinibEGFRgastric adenocarcinomahypotensionlung adenocarcinoma

Identifiers

PMID40678071
PMCPMC12267000

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.